Human immunodeficiency virus antibodies and the vaccine problem. (Q38192126)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24581142 AND SRC:MED&resulttype=core&format=json

9 March 2020

review article

1 reference

title

Human immunodeficiency virus antibodies and the vaccine problem (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24581142 AND SRC:MED&resulttype=core&format=json

9 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24581142 AND SRC:MED&resulttype=core&format=json

9 March 2020

author name string

R A Weiss

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24581142 AND SRC:MED&resulttype=core&format=json

9 March 2020

language of work or name

English

0 references

publication date

1 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24581142 AND SRC:MED&resulttype=core&format=json

Journal of Internal Medicine

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24581142 AND SRC:MED&resulttype=core&format=json

9 March 2020

volume

275

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24581142 AND SRC:MED&resulttype=core&format=json

9 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24581142 AND SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

444-455

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24581142 AND SRC:MED&resulttype=core&format=json

Accelerating next-generation vaccine development for global disease prevention

9 March 2020

cites work

1 reference

Flaviviruses and flavivirus vaccines

21 January 2018

1 reference

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

21 January 2018

1 reference

Broadly neutralizing antiviral antibodies

21 January 2018

1 reference

Fc receptor-mediated antiviral antibodies

21 January 2018

1 reference

Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.

21 January 2018

1 reference

Immune clearance of highly pathogenic SIV infection

21 January 2018

1 reference

Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking.

21 January 2018

1 reference

Vaccine adjuvants: the future is bright. Interview by Jenaid Rees

21 January 2018

1 reference

Vaccine adjuvants: a priority for vaccine research

21 January 2018

1 reference

Live attenuated HIV vaccines: pitfalls and prospects

21 January 2018

1 reference

21 January 2018

Why is HIV a pathogen?

1 reference

HIV interactions with monocytes and dendritic cells: viral latency and reservoirs

21 January 2018

1 reference

Prevention strategies against small ruminant lentiviruses: an update

21 January 2018

1 reference

Origins of HIV and the AIDS Pandemic

21 January 2018

1 reference

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

21 January 2018

1 reference

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

21 January 2018

1 reference

Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission

21 January 2018

1 reference

Macaca mulatta, fascicularis and nemestrina in AIDS vaccine development.

21 January 2018

1 reference

Infectious diseases in humanized mice

21 January 2018

1 reference

Antibody-based protection against HIV infection by vectored immunoprophylaxis

21 January 2018

1 reference

21 January 2018

1 reference

Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection

21 January 2018

1 reference

A Blueprint for HIV Vaccine Discovery

21 January 2018

1 reference

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

21 January 2018

1 reference

Development of prophylactic vaccines against HIV-1.

21 January 2018

1 reference

The Antibody Response against HIV-1

21 January 2018

1 reference

Antibody neutralization and escape by HIV-1

21 January 2018

1 reference

Phenotypic properties of transmitted founder HIV-1

21 January 2018

1 reference

Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization

21 January 2018

1 reference

The changing face of HIV vaccine research

21 January 2018

1 reference

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

21 January 2018

1 reference

Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans

21 January 2018

1 reference

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

21 January 2018

1 reference

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals

21 January 2018

1 reference

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

21 January 2018

1 reference

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

21 January 2018

1 reference

Neutralizing antibodies to HIV-1 induced by immunization.

21 January 2018

1 reference

Duration of humoral immunity to common viral and vaccine antigens

21 January 2018

1 reference

Impairment of B-cell functions during HIV-1 infection.

21 January 2018

1 reference

Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection

21 January 2018

1 reference

Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children

21 January 2018

1 reference

Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals

21 January 2018

1 reference

Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors

21 January 2018

1 reference

B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection

21 January 2018

1 reference

Class switch recombination: a comparison between mouse and human.

21 January 2018

1 reference

Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques.

21 January 2018

1 reference

The PD-1-PD-L pathway in immunological tolerance

21 January 2018

1 reference

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

21 January 2018

1 reference

Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster

21 January 2018

1 reference

Designing tomorrow's vaccines

21 January 2018

1 reference

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

21 January 2018

1 reference

Structural biology. Is high-tech view of HIV too good to be true?

21 January 2018

1 reference

Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer

21 January 2018

1 reference

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

21 January 2018

1 reference

A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition

21 January 2018

1 reference

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies

21 January 2018

1 reference

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

21 January 2018

1 reference

Humoral immunity to HIV-1: neutralisation and antibody effector functions

21 January 2018

1 reference

Antibody-dependent enhancement and the risk of HIV infection

21 January 2018

1 reference

Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection

21 January 2018

1 reference

Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women

21 January 2018

1 reference

HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4( ) cell infection: an IgA gene and functional analysis

21 January 2018

1 reference

Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody

21 January 2018

1 reference

Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice

21 January 2018

1 reference

Antibodies in HIV-1 vaccine development and therapy

21 January 2018

1 reference

Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference.

21 January 2018

1 reference

Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus.

21 January 2018

1 reference

Llama antibody fragments have good potential for application as HIV type 1 topical microbicides.

21 January 2018

1 reference